Pfenex Inc (NYSEMKT:PFNX)‘s stock had its “ourperform” rating reiterated by equities research analysts at William Blair in a research note issued on Friday.

Several other equities research analysts have also recently weighed in on PFNX. ValuEngine cut Pfenex from a “hold” rating to a “sell” rating in a report on Saturday, June 3rd. Zacks Investment Research upgraded Pfenex from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Thursday, July 13th.

Pfenex (NYSEMKT:PFNX) traded down 0.29% during trading on Friday, hitting $3.49. 13,452 shares of the stock were exchanged. The stock has a market cap of $82.11 million, a price-to-earnings ratio of 56.29 and a beta of 4.65. Pfenex has a 1-year low of $3.16 and a 1-year high of $11.35. The firm’s 50 day moving average price is $3.93 and its 200-day moving average price is $4.84.

Pfenex (NYSEMKT:PFNX) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.06. The firm had revenue of $3.03 million for the quarter, compared to the consensus estimate of $3.10 million. Pfenex had a negative net margin of 406.87% and a negative return on equity of 75.61%. Pfenex’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.43) earnings per share. On average, analysts anticipate that Pfenex will post ($2.09) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at

In other Pfenex news, Director Jason Grenfell-Gardner acquired 10,000 shares of the company’s stock in a transaction on Monday, June 12th. The stock was acquired at an average price of $4.51 per share, for a total transaction of $45,100.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $45,100. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strs Ohio lifted its holdings in Pfenex by 8.2% in the 2nd quarter. Strs Ohio now owns 18,400 shares of the biotechnology company’s stock worth $154,000 after buying an additional 1,400 shares during the period. Russell Investments Group Ltd. lifted its holdings in Pfenex by 221.0% in the 1st quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock worth $187,000 after buying an additional 22,160 shares during the period. Goldman Sachs Group Inc. purchased a new stake in Pfenex in the 1st quarter worth approximately $198,000. Algert Global LLC lifted its holdings in Pfenex by 207.3% in the 1st quarter. Algert Global LLC now owns 34,603 shares of the biotechnology company’s stock worth $201,000 after buying an additional 23,344 shares during the period. Finally, Prudential Financial Inc. lifted its holdings in Pfenex by 7.7% in the 1st quarter. Prudential Financial Inc. now owns 25,120 shares of the biotechnology company’s stock worth $247,000 after buying an additional 1,800 shares during the period.

Pfenex Company Profile

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with's FREE daily email newsletter.